XOMA - Dividend announcements

EMERYVILLE, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors approved a dividend of $0.71875 per share to holders of XOMA’s Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP).  The cash dividend will be paid on or about April 15, 2021, to XOMAP holders of record at the close of business on April 2, 2021. About XOMA CorporationXOMA has built a significant portfolio of products that are licensed to and being developed by other biotech and pharmaceutical companies.  The Company’s portfolio of partner-funded programs spans multiple stages of the drug development process and across various th

Recognized revenue of $29.4 million Six assets in the Company’s milestone and royalty portfolio advanced to Phase 2 clinical development Completed $24.6 million Series A Perpetual Preferred Stock offering paying a 8.625% dividend Ended 2020 with $84.2 million in cash EMERYVILLE, Calif., March 10, 2021 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) announced its fourth quarter and full-year 2020 financial results and business highlights. “Our success in 2020 is a direct reflection of our strategy at work.  As a result of the commitment by our partners to improve human health, we saw multiple programs advance further in the clinic.  Novartis, Merck, Takeda, Incyte, Rezolute, and an u